PCVX - Vaxcyte, Inc.

58.25
-1.880   -3.227%

Share volume: 1,324,745
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$60.13
-1.88
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.02%
1 Month
3.74%
3 Months
26.14%
6 Months
79.73%
1 Year
-22.14%
2 Year
-18.19%
Key data
Stock price
$58.25
P/E Ratio 
0.00
DAY RANGE
$56.87 - $59.73
EPS 
-$5.43
52 WEEK RANGE
$27.66 - $76.61
52 WEEK CHANGE
-$18.17
MARKET CAP 
6.040 B
YIELD 
N/A
SHARES OUTSTANDING 
143.920 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
-0.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,522,505
AVERAGE 30 VOLUME 
$1,347,551
Company detail
CEO: Grant E. Pickering
Region: US
Website: vaxcyte.com
Employees: 160
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.

Recent news